Table 2 Dosimetric baseline characteristics of patients who developed RP and non-RP patients
Variable | RTOG | CTCAE | ||||
|---|---|---|---|---|---|---|
No pneumonitis n = 26 | Pneumonitis n = 11 | P value | No pneumonitis n = 22 | Pneumonitis n = 15 | P value | |
GTV (cm3) | 75.6 (41.3134) | 135 (49.4265) | 0.17 | 80.8 (39.8135) | 112 (41.4252) | 0.52 |
PTV (cm3) | 321 (216,420) | 444 (267,581) | 0.14 | 322 (221,428) | 392 (194,581) | 0.3 |
Absolute dose (Gy) | ||||||
≤ 60 | 7 (26.9) | 5 (45.5) | 0.43 | 5 (22.7%) | 7 (46.7%) | 0.12 |
> 60 | 19 (73.1) | 6 (54.5) | 17 (77.3%) | 8 (53.3%) | ||
Dose per fraction (cGy) | ||||||
180–200 | 20 (76.9%) | 5 (45%) | 0.12 | 18 (81.8%) | 7 (50%) | 0.036 |
250 | 6 (23.1%) | 6 (54%) | 4 (18.2%) | 8 (50%) | ||
Restriction dose (%) | ||||||
V 5 | 65 (56.5,77.9) | 54.9 (47, 69.4) | 0.17 | 65.5 (56,79) | 56.8 (48,70) | 0.19 |
V 20 | 49.7 (41, 57.2) | 42 (27.7,55.5) | 0.4 | 49.7 (39,57.9) | 44 (32,59.4) | 0.62 |
MLD (Gy) | 26 (18.5, 29.2) | 20 (13,30) | 0.57 | 25.8 (18,29.6) | 21.4 (15,29) | 0.53 |